Vaxcyte CEO Grant Pickering Sells Over 23,000 Shares

Grant Pickering, CEO of Vaxcyte, sold 23,461 shares in a planned transaction on June 18, 2026.

Written by EarningsIQ · Published Jun 18, 2026, 9:00 PM EDT · Updated Jun 18, 2026, 10:00 PM EDT

Key Points

Grant Pickering, CEO of Vaxcyte, Inc., sold 23,461 shares worth approximately $1.23 million on June 18, 2026.
Shares of Vaxcyte on NasdaqGS traded around $50.67, with a market cap of approximately $7.32 billion.
Analysts maintain a strong buy consensus on Vaxcyte, with a mean price target of $109.

On June 18, 2026, Grant Pickering, the CEO of Vaxcyte, Inc. (NasdaqGS: PCVX), sold 23,461 shares of the company's stock. The shares were sold at an average price of $52.50 each, totaling approximately $1.23 million. This transaction was part of a planned sale under Rule 10b5-1.

What Changed in Grant Pickering's Vaxcyte Position

Grant Pickering reduced his holdings in Vaxcyte by 23,461 shares on June 18, 2026. The shares were sold at an average price of $52.50, bringing the total value of the transaction to about $1.23 million. This sale was part of a planned transaction.

Other Institutional Activity in Vaxcyte

Several institutional investors have also been active in Vaxcyte. Janus Henderson Group PLC increased its holdings by 3,188,687 shares, bringing its total to 16,575,875 shares valued at about $960.2 million. FMR LLC added 2,658,347 shares, totaling 16,492,861 shares worth approximately $958.4 million. T. Rowe Price Investment Management, Inc. grew its position by 829,684 shares, ending with 12,126,017 shares valued at $704.6 million. RA Capital Management, L.P. added 750,000 shares, bringing its total to 11,474,599 shares, worth around $666.8 million.

Vaxcyte Stock Snapshot

Shares of Vaxcyte, Inc. (NasdaqGS: PCVX) recently traded at around $50.67. The company has a market capitalization of approximately $7.32 billion. While not currently profitable, Vaxcyte's forward P/E ratio is not meaningful. The stock's beta is 1.242, indicating moderate volatility. Over the past 52 weeks, the stock has ranged from a low of $29.08 to a high of $65.00. It has a 50-day moving average of $53.89 and a 200-day moving average of $48.95. The company maintains a strong current ratio of 7.49.

Insider Buying and Selling at Vaxcyte, Inc.

On June 18, 2026, several insiders at Vaxcyte were active. CEO Grant Pickering sold 23,461 shares at an average price of $52.50 as part of a planned transaction. Meanwhile, Andrew Guggenhime, President and CFO, bought 10,000 shares at $5.35 and sold another 10,000 shares at $53.00, with the latter sale also being planned.

Analysts Set New Price Targets

Analysts continue to show strong interest in Vaxcyte. On February 26, 2026, BTIG maintained its 'buy' rating with a price target of $89. Guggenheim reiterated its 'buy' rating with a target of $116 on February 2, 2026. Needham also maintained a 'buy' rating with a $110 target on January 7, 2026. Currently, Vaxcyte holds a consensus 'strong buy' rating with an average price target of $109 from nine analysts.

About Vaxcyte, Inc.

Vaxcyte, Inc. is a biotechnology company focused on developing vaccines to prevent or treat bacterial infectious diseases. Headquartered in San Carlos, California, Vaxcyte is working on several vaccine candidates, including VAX-24 and VAX-31 for pneumococcal disease, VAX-A1 for Group A Streptococcus, and VAX-PG for periodontitis. The company is led by CEO Grant Pickering and employs around 507 people.

Bottom Line

Grant Pickering's planned sale of Vaxcyte shares is a notable insider transaction, reflecting ongoing activity within the company's executive ranks. Vaxcyte remains a focus for institutional investors and analysts, with a strong buy recommendation and a high average price target. Investors should note that 13F filings and insider transactions are historical and may not represent current conditions.